title: When should nitroglycerine be avoided in hypertensive encephalopathy?
authors.forename: Mohamed A
authors.initials: MA
authors.lastname: Sheta
authors.forename: Madhu
authors.initials: M
authors.lastname: Paladugu
authors.forename: Joshua
authors.initials: J
authors.lastname: Mendelson
authors.forename: Neil R
authors.initials: NR
authors.lastname: Holland
mesh_terms: D000075202:Contraindications; D018450:Disease Progression; D005500:Follow-Up Studies; D006801:Humans; D020343:Hypertensive Encephalopathy / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D007262:Infusions, Intravenous; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D008875:Middle Aged; D009460:Neurologic Examination / Q000379:methods; D005996:Nitroglycerin / Q000008:administration & dosage; D018570:Risk Assessment; D012720:Severity of Illness Index; D014057:Tomography, X-Ray Computed / Q000379:methods; D016896:Treatment Outcome
chemical_list: D005996:Nitroglycerin